查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612744

癌症干细胞市场：按类型、来源、癌症类型、应用、最终用户划分 - 2025-2030 年全球预测

Cancer Stem Cells Market by Type (Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell), Source (Allogenic, Autologous), Cancer Type, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌症干细胞市场价值为47.2亿美元，预计到2024年将达到52.1亿美元，复合年增长率为10.55%，到2030年将达到95.4亿美元。

癌症干细胞（CSC）是癌细胞的一个亚群，能够自我更新并分化成肿瘤中发现的各种细胞类型。 CSC在癌症增殖、转移和復发中发挥重要作用，并且在癌症研究和治疗开发中变得越来越重要。对 CSCs 研究的需求有可能透过靶向有助于抗药性和肿瘤异质性的细胞来彻底改变癌症治疗。 CSC 研究的应用范围从药物开发到个人化医疗，旨在提高现有癌症治疗的有效性并降低復发率。最终用途范围包括许多生物技术公司、製药公司和专注于肿瘤学的学术研究机构。

主要市场统计
基准年[2023] 47.2亿美元
预测年份 [2024] 52.1亿美元
预测年份 [2030] 95.4亿美元
复合年增长率（%） 10.55%

CSC 研究市场是由癌症发病率上升、干细胞研究技术进步以及对个人化医疗日益增长的兴趣所推动的。商业机会存在于开髮用于 CSC 识别的新型生物标记和特异性中和 CSC 而不损害正常细胞的标靶治疗。大力投资癌症研究的政府和私人组织提供了进一步的合作和资金筹措机会。然而，由于高昂的研究成本、监管障碍和伦理问题，特别是在干细胞的使用方面，市场成长面临挑战。对CSC相对浅薄的生物学认识也是一个主要限制，阻碍了有效治疗方法的发现和发展。

在创新和研究方面，探索CSC的遗传和表观遗传景观可能会揭示新的治疗标靶。开发选择性靶向这些细胞的无毒 CSC 抑制剂和基于免疫的治疗方法是一个有前途的领域。另一个创新领域是利用人工智慧来预测 CSC 行为和治疗反应，这有可能显着增强药物开发过程。市场的本质是动态的，快速的科学进步创造了一个高度竞争的环境。能够利用尖端研究提供有效、个人化癌症治疗的公司将获得显着的竞争优势。

市场动态：揭示快速发展的癌症干细胞市场的关键市场洞察

供需的动态交互作用正在改变癌症干细胞市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全世界对癌症的认识不断增强以及对有效治疗方法的需求
    • 政府对干细胞研究的支持政策和奖励
  • 市场限制因素
    • 干细胞研究的严格监管框架
  • 市场机会
    • 癌症研究的基因组定序与生物技术创新
    • 学术机构和生物製药公司之间加强干细胞研究合作
  • 市场挑战
    • 癌症干细胞的复杂性与干细胞异质性和可塑性有关

波特五力策略工具引领癌症干细胞市场

波特的五力框架是了解癌症干细胞市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对癌症干细胞市场的影响

外部宏观环境因素在塑造癌症干细胞市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症干细胞市场的竞争格局

癌症干细胞市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵癌症干细胞市场供应商的绩效评估

FPNV定位矩阵是评估癌症干细胞市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製癌症干细胞市场的成功之路

癌症干细胞市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地对癌症的认识不断提高，对有效治疗方法的需求也增加。
      • 支持干细胞研究的政府政策和奖励
    • 抑制因素
      • 干细胞研究的严格法规结构
    • 机会
      • 癌症研究的基因组定序与生物技术创新
      • 加强学术机构与生物製药公司在干细胞研究的合作
    • 任务
      • 与癌症干细胞异质性和可塑性相关的复杂性
  • 市场区隔分析
    • 类型：在癌症生物学中使用人类 ES 细胞来了解癌症机制并支持标靶癌症治疗方法的开发
    • 癌症类型：癌症干细胞越来越多地用于需要有效治疗和治疗的各种癌症诊断
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症干细胞市场：依类型

  • 成体干细胞
  • 人类胚胎干细胞
  • 诱导性多功能细胞

第七章癌症干细胞市场：依来源分类

  • 同种异体的
  • 自体移植

第 8 章按癌症类型分類的癌症干细胞市场

  • 乳癌
  • 肺癌
  • 摄护腺癌

第九章癌症干细胞市场：依应用分类

  • 临床调查
  • 药物开发
  • 标靶治疗

第 10 章癌症干细胞市场：依最终用户分类

  • 学术研究所
  • 医院和细胞库
  • 製药和生物技术公司

第十一章美洲癌症干细胞市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区癌症干细胞市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的癌症干细胞市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • StemCell Technologies 透过收购 Propagenix 来加强产品组合，并开始推动癌症干细胞研究
    • Astra Zeneca透过收购 Graycell Biotechnologies 增强细胞治疗能力
    • Max Healthcare 与Immunoact 合作推出先进的 CAR-T 细胞疗法
  • 战略分析和建议

公司名单

  • AcceGen
  • Becton, Dickinson and Company
  • Bio-Techne Corporation
  • Biorestorative Therapies Inc.
  • BrainStorm Cell Limited
  • Gamida Cell Ltd.
  • GenScript Biotech Corporation
  • JCR Pharmaceuticals Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Novartis AG
  • Qiagen NV
  • Sartorius AG
  • STEMCELL Technologies Canada Inc.
  • Takara Bio Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-99555D550527

The Cancer Stem Cells Market was valued at USD 4.72 billion in 2023, expected to reach USD 5.21 billion in 2024, and is projected to grow at a CAGR of 10.55%, to USD 9.54 billion by 2030.

Cancer Stem Cells (CSCs) are a subpopulation of cancer cells possessing the ability to self-renew and differentiate into various cell types found in tumors. They play a crucial role in cancer proliferation, metastasis, and recurrence, which elevates their importance in cancer research and therapy development. The necessity of CSCs research lies in their potential to revolutionize cancer treatment by targeting cells that contribute to drug resistance and tumor heterogeneity. Applications of CSC research span from drug development to personalized medicine, aiming to enhance the efficacy of existing cancer treatments and reduce relapse rates. The end-use scope prominently includes biotechnology firms, pharmaceutical companies, and academic research institutions focused on oncology.

KEY MARKET STATISTICS
Base Year [2023] USD 4.72 billion
Estimated Year [2024] USD 5.21 billion
Forecast Year [2030] USD 9.54 billion
CAGR (%) 10.55%

The market for CSC research is driven by increasing cancer prevalence, technological advancements in stem cell research, and growing interest in personalized medicine. Opportunities exist in the development of novel biomarkers for CSC identification and targeted therapeutics that specifically neutralize CSCs without harming normal cells. Governments and private entities investing heavily in cancer research present additional opportunities for collaborations and funding. However, market growth faces challenges due to high research costs, regulatory hurdles, and ethical concerns, particularly concerning stem cell usage. A significant limitation is the relatively nascent understanding of CSC biology, which can impede the discovery and development of effective therapies.

In terms of innovation and research, exploring the genetic and epigenetic landscapes of CSCs could unveil new therapeutic targets. Developing non-toxic CSC inhibitors or immune-based therapies to selectively target these cells is a promising area. Another innovative field is the utilization of artificial intelligence to predict CSC behavior and treatment responses, which could significantly enhance drug development processes. The nature of the market is dynamic, with rapid scientific advancements creating a highly competitive environment. Companies that can leverage cutting-edge research to offer effective, personalized cancer treatments are positioned to gain a significant competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Stem Cells Market

The Cancer Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness of cancer worldwide and the need for effective therapeutic options
    • Supportive government policies and incentives for stem cell research
  • Market Restraints
    • Stringent regulatory frameworks for stem cell research
  • Market Opportunities
    • Innovations in genomics sequencing and biotechnology for cancer research
    • Increased collaboration between academic institutions and biopharmaceutical companies for stem cell research
  • Market Challenges
    • Complexities associated with the heterogeneity and plasticity of cancer stem cells

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Stem Cells Market

A detailed market share analysis in the Cancer Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Stem Cells Market

A strategic analysis of the Cancer Stem Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Stem Cells Market, highlighting leading vendors and their innovative profiles. These include AcceGen, Becton, Dickinson and Company, Bio-Techne Corporation, Biorestorative Therapies Inc., BrainStorm Cell Limited, Gamida Cell Ltd., GenScript Biotech Corporation, JCR Pharmaceuticals Co., Ltd., Lonza Group Ltd., Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novartis AG, Qiagen N.V, Sartorius AG, STEMCELL Technologies Canada Inc., Takara Bio Inc., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Adult Stem Cell, Human Embryonic Stem Cell, and Induced Pluripotent Stem Cell.
  • Based on Source, market is studied across Allogenic and Autologous.
  • Based on Cancer Type, market is studied across Breast Cancer, Lung Cancer, and Prostate Cancer.
  • Based on Application, market is studied across Clinical Research, Drug Development, and Targeted Therapy.
  • Based on End-User, market is studied across Academic & Research Institutes, Hospitals & Cell Banks, and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness of cancer worldwide and the need for effective therapeutic options
      • 5.1.1.2. Supportive government policies and incentives for stem cell research
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory frameworks for stem cell research
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in genomics sequencing and biotechnology for cancer research
      • 5.1.3.2. Increased collaboration between academic institutions and biopharmaceutical companies for stem cell research
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with the heterogeneity and plasticity of cancer stem cells
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Utilization of hESCs in cancer biology to understand cancer mechanisms and support the development of targeted cancer therapies
    • 5.2.2. Cancer Type: Increasing usage of cancer stem cells in varied cancer diagnoses to necessitates effective treatments and therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Adult Stem Cell
  • 6.3. Human Embryonic Stem Cell
  • 6.4. Induced Pluripotent Stem Cell

7. Cancer Stem Cells Market, by Source

  • 7.1. Introduction
  • 7.2. Allogenic
  • 7.3. Autologous

8. Cancer Stem Cells Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Lung Cancer
  • 8.4. Prostate Cancer

9. Cancer Stem Cells Market, by Application

  • 9.1. Introduction
  • 9.2. Clinical Research
  • 9.3. Drug Development
  • 9.4. Targeted Therapy

10. Cancer Stem Cells Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Hospitals & Cell Banks
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Cancer Stem Cells Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Stem Cells Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Stem Cells Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. StemCell Technologies Enhances Portfolio with Propagenix Acquisition to Advance Cancer Stem Cell Research
    • 14.3.2. AstraZeneca Enhances Cell Therapy Capabilities with Gracell Biotechnologies Acquisition
    • 14.3.3. Max Healthcare Initiates Advanced CAR-T Cell Therapy in Partnership with ImmunoACT
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AcceGen
  • 2. Becton, Dickinson and Company
  • 3. Bio-Techne Corporation
  • 4. Biorestorative Therapies Inc.
  • 5. BrainStorm Cell Limited
  • 6. Gamida Cell Ltd.
  • 7. GenScript Biotech Corporation
  • 8. JCR Pharmaceuticals Co., Ltd.
  • 9. Lonza Group Ltd.
  • 10. Merck KGaA
  • 11. Miltenyi Biotec B.V. & Co. KG
  • 12. Novartis AG
  • 13. Qiagen N.V
  • 14. Sartorius AG
  • 15. STEMCELL Technologies Canada Inc.
  • 16. Takara Bio Inc.
  • 17. Takeda Pharmaceutical Company Limited
  • 18. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER STEM CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. CANCER STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. CANCER STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER STEM CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER STEM CELLS MARKET SIZE, BY ADULT STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER STEM CELLS MARKET SIZE, BY HUMAN EMBRYONIC STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER STEM CELLS MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER STEM CELLS MARKET SIZE, BY ALLOGENIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER STEM CELLS MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER STEM CELLS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER STEM CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER STEM CELLS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER STEM CELLS MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER STEM CELLS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER STEM CELLS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER STEM CELLS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER STEM CELLS MARKET SIZE, BY HOSPITALS & CELL BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER STEM CELLS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CANCER STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CANCER STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. CANCER STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. CANCER STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023